Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 811 results for "ldl"

Anti-LDL Drug Praluent Gets FDA Approval, But Itll Cost You
Modern Readers

Sanofi/Regeneron's LDL-Lowering Praluent Beats Competitor to U...

The FDA gave the green light to Sanofi and Regeneron's cholesterol-lowering drug Praluent, beating Amgen's Repatha in a race to be the first PCSK9 inhibitor in the U.S. PCSK9 inhibitors work by blocking a particular protein which increases the ... FDA News, 1 day ago

Sanofi and Regeneron Pharmaceuticals awarded US FDA approval for Praluent Injection for treating High LDL cholesterol in adult patients

Therapeutic solution company Sanofi (Paris:SAN.PA) and Regeneron Pharmaceuticals jointly disclosed the receipt of US Food and Drug Administration (FDA) approval for Praluent (alirocumab) Injection for treating High LDL cholesterol in adult patients.
 Bloomberg5 days ago
Sys-Con Media

Global Statin Market 2015-2019

/PRNewswire/ -- About Statin Statin is a structural analog of HMG-CoA enzyme and is effective in reducing LDL. It shows its pharmaceutical action by inhibiting the key enzyme involved in cholesterol synthesis, which is called HMG-CoA reductase.
 Franklin Credit Management Corporation3 days ago Research and Markets: Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating  Yahoo! Finance UK and Ireland1 day ago Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating  Individual.com1 day ago Global Clinical Chemistry and Immunodiagnostics Market Strategies 2015-2020  Individual.com4 days ago
Sys-Con Media

Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension

) - The six-week study met its primary endpoint of greater LDL-cholesterol lowering from baseline with ETC-1002 as compared to placebo. Patients treated with 180 mg of ETC-1002 achieved a 21 percent reduction in LDL-cholesterol from baseline (p ...
 Pettinga Financial Advisors4 days ago Esperion Therapeutics (ESPR) Announces Positive Top-Line Phase 2 Results For ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/28/2015  ClinicSpace3 days ago Esperion Therapeutics to Provide Second Quarter Program Updates and Financial Results  Pettinga Financial Advisors2 days ago Esperion looks to disrupt the PCSK9 race with new cardio data  FierceBiotech3 days ago

A new way of lowering LDL cholesterol: Part 2

Earlier this week , we discussed two novel drugs that could potentially revolutionize the treatment and prevention of cardiovascular disease. Both drugs are antibodies, and work by an entirely new mechanism—by binding to, and inactivating a ...
 American Council On Science & Health1 day ago
Renal & Urology News

Praluent looks cheap to those with extreme cholesterol

The newly approved cholesterol alirocumab (Praluent—Sanofi-Aventis) can drive levels of LDL cholesterol into the 20s or even the teens, numbers almost never before seen in adults. In general, it lowers cholesterol by 50% to 70%, compared with 25% ...
 Pharmacist.com3 days ago Praluent Approved to Treat High Cholesterol  DangoteNews.com3 days ago FDA approves Praluent to treat certain patients with high cholesterol  PressReleasePoint3 days ago FDA OKs First of New Class of Cholesterol Drugs  DangoteNews.com4 days ago

Lowering LDL Cholesterol Is Good, but How and in Whom? Editorial

Download the PDF here Neil J. Stone, M.D., and Donald M. Lloyd-Jones, M.D. N Engl J Med 2015 April 16 Genetic findings reported approximately 9 years ago in the Journal indicated that rare sequence variants in the gene encoding proprotein ...
 National AIDS Treatment Advocacy Project2 days ago
American Council On Science & Health

The FDA approved the first of a new class of cholesterol-lowering drugs that can reduce LDL cholesterol by between 36 and 59 percent.

Drug that dramatically lowers cholesterol approved by FDA Jul. 24. /UPI/ -- Copyright 2015 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited ...
 TickerTech.com1 week ago Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction  PharmaVOICE1 week ago FDA approves new cholesterol drug - at $14,600 a year  National AIDS Treatment Advocacy Project2 days ago New cholesterol drug comes with hefty price tag  Shanghai Daily2 days ago

Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to NonRheumatoid Arthritis Patients

Objective Lower levels of low-density lipoprotein (LDL) cholesterol may be associated with increased cardiovascular (CV) risk in rheumatoid arthritis (RA). This study was undertaken to determine whether the complex relationship between levels of ...
 Arthritis & Rheumatism3 days ago

Will Regeneron (REGN) Earnings Surprise on Eylea Sales?

Regeneron Pharmaceuticals, Inc. ( REGN - Analyst Report ) is scheduled to release second-quarter 2015 financial results before the opening bell on Aug 4, 2015. The company has recorded positive earnings surprises in one of the trailing four ...
 Zacks.com17 hours ago PFIZER REPORTS SECOND-QUARTER 2015 RESULTS  FierceVaccines2 days ago The Medicines Company Reports Second-Quarter and First-Half 2015 Financial Results  Yahoo! Finance UK and Ireland3 days ago Merck Announces Second-Quarter 2015 Financial Results  Citybizlist3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less